Результати пошуку - Tim Clay

595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab за авторством Enriqueta Felip, Christian Mueller, Martin Forster, Tim Clay, Matthew Krebs, Frederic Triebel, Enric Carcereny, Ewa Kalinka, Margarita Majem, Bernard Doger, Julio Peguero, Chrystelle Brignone, Igor Bondarenko, Wade T Iams, Manuel Cobo Dols, Grygorii Ursol, Gema Garcia Ledo, Laia Vilà Martinez

Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1... за авторством Matthew G. Krebs, MD, Martin Forster, MD, PhD, Margarita Majem, MD, PhD, Julio Peguero, MD, Wade Iams, MD, Tim Clay, MD, Patricia Roxburgh, MD, PhD, Bernard Doger, MD, PhD, Pawan Bajaj, MD, Andres Barba, MD, Suvini Perera, MS, Christian Mueller, MS, Frédéric Triebel, MD, PhD

Отримати повний текст